@article{fcb33e09d96e4f1caa0b8f73725d8aa2,
title = "Molecular Targeted Therapies in Hepatocellular Carcinoma: Past, Present and Future.",
keywords = "RANDOMIZED PHASE-III, SINGLE-AGENT SORAFENIB, LIVER-TRANSPLANTATION, ONCOLYTIC POXVIRUS, PLUS SORAFENIB, CLINICAL-TRIAL, RISK-FACTORS, OPEN-LABEL, CANCER, EFFICACY",
author = "Michael Stotz and Armin Gerger and Johannes Haybaeck and Tobias Kiesslich and Bullock, \{Marc D\} and Martin Pichler",
note = "Kiesslich: Department of Internal Medicine I, Institute of Physiology and Pathophysiology, Paracelsus Medical University, Salzburg, Austria Laboratory for Tumor Biology and Experimental Therapies, Institute of Physiology and Pathophysiology, Paracelsus Medical University, Salzburg, Austria.",
year = "2015",
language = "English",
volume = "35",
pages = "5737--5744",
journal = "ANTICANCER RESEARCH ",
issn = "0250-7005",
number = "11",
}